James Noble - GW Pharmaceuticals Chairman
Chairman
Mr. James Julian Noble is NonExecutive Deputy Chairman of the Board, Senior Independent Director of GW Pharmaceuticals PLC. Mr. Noble has 20 years of experience in the biotech industry. Mr. Noble currently serves as Chief Executive Officer of Immunocore Limited and Adaptimmune Limited, two privatelyheld companies involved in Tcell receptor technology. Mr. Noble has previously held numerous nonexecutive director positions, including at CuraGen Corporationrationration, PowderJect Pharmaceuticals plc, Oxford GlycoSciences plc, MediGene AG, and Advanced Medical Solutions plc. Mr. Noble is qualified as a chartered accountant with Price Waterhouse and spent seven years at the investment bank Kleinwort Benson Limited, where he became a director in 1990. He then joined British Biotech plc as Chief Financial Officer and secured the company IPO on the Nasdaq and London stock exchanges in 1992. Mr. Noble was previously Chief Executive Officer of Avidex Limited, a privatelyheld biotechnology company. Mr. Noble holds an M.A. from the University of Oxford. Our board of directors believes Mr. Noble qualifications to serve as a member of our board include his financial expertise, his extensive experience in the pharmaceutical industry and his years of experience in his leadership roles as a director and executive officer. since 2007.
| Age | 54 |
| Tenure | 17 years |
| Phone | (44) 1223 235667 |
| Web | www.gwpharm.com |
GW Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (3.55) % which means that it has lost $3.55 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.92) %, meaning that it created substantial loss on money invested by shareholders. GW Pharmaceuticals' management efficiency ratios could be used to measure how well GW Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 43.64 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. GW Pharmaceuticals Plc has a current ratio of 4.48, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist GW Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, GW Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like GW Pharmaceuticals Plc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for GWPH to invest in growth at high rates of return. When we think about GW Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 9 records | CHAIRMAN Age | ||
| Diane Sullivan | Brp Group | 61 | |
| Patrice Motsepe | Harmony Gold Mining | 56 | |
| Modise Motloba | Harmony Gold Mining | 51 | |
| Aldo Zucaro | Old Republic International | 80 | |
| Reginald Gillard | Perseus Mining Limited | 66 | |
| James Kellogg | Old Republic International | 62 | |
| Rande Yeager | Old Republic International | 75 | |
| Scott Rager | Old Republic International | 69 | |
| Howard Lance | Summit Materials | 65 | |
Management Performance
| Return On Equity | -7.92 | |||
| Return On Asset | -3.55 |
GW Pharmaceuticals Plc Leadership Team
Elected by the shareholders, the GW Pharmaceuticals' board of directors comprises two types of representatives: GW Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GWPH. The board's role is to monitor GW Pharmaceuticals' management team and ensure that shareholders' interests are well served. GW Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GW Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| William Waldegrave, Non-Executive Independent Director | ||
| Christopher Tovey, COO, Executive Director | ||
| Thomas Lynch, Non-Executive Independent Director | ||
| Catherine Mackey, Non-Executive Independent Director | ||
| Justin Gover, CEO, Director | ||
| Geoffrey Guy, Executive Chairman of the Board | ||
| James Noble, Non-Executive Deputy Chairman of the Board, Senior Independent Director | ||
| Julian Gangolli, Executive Director | ||
| Alicia Secor, Non-Executive Independent Director | ||
| Adam George, CFO, Company Secretary, Director | ||
| Cabot Brown, Non-Executive Independent Director | ||
| Stephen Wright, Research & Development Director, Executive Director | ||
| Darren Cline, Chief Commercial Officer, U.S. |
GWPH Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GW Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -7.92 | |||
| Return On Asset | -3.55 | |||
| Profit Margin | (11.03) % | |||
| Operating Margin | (9.82) % | |||
| Current Valuation | 6.42 B | |||
| Shares Outstanding | 31.54 M | |||
| Shares Owned By Insiders | 0.20 % | |||
| Shares Owned By Institutions | 80.35 % | |||
| Number Of Shares Shorted | 693.73 K | |||
| Price To Earning | 126.70 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Other Consideration for investing in GWPH Stock
If you are still planning to invest in GW Pharmaceuticals Plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the GW Pharmaceuticals' history and understand the potential risks before investing.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |